ReviewEJNMMI radiopharmacy and chemistry2019
Molecular imaging of multiple sclerosis: from the clinical demand to novel radiotracers.
Review in EJNMMI radiopharmacy and chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Non-conventional and Investigational PET Radiotracers for Breast Cancer: A Systematic Review.Frontiers in medicine · 2022Pooled it
- Astrocyte Activation Persists after Recovery of Myelin and Motor Deficits in the Cuprizone Model: a Longitudinal PET and CNS Tissue Analysis Study.Molecular imaging and biology · 2026Article
- Translational molecular imaging and drug development in multiple sclerosis.Theranostics · 2026Review
- The Future of PET Imaging in Multiple Sclerosis: Characterisation of Individual White Matter Lesions.Journal of clinical medicine · 2025Review
- Medical Digital Twin: A Review on Technical Principles and Clinical Applications.Journal of clinical medicine · 2025Review
- Microglia positron emission tomography and progression in multiple sclerosis: thalamus on fire.Brain communications · 2025Article
- Tumefactive demyelinating lesions: A literature review of recent findings.Neurosciences (Riyadh, Saudi Arabia) · 2024Review
- Advanced MRI Techniques: Diagnosis and Follow-Up of Multiple Sclerosis.Diagnostics (Basel, Switzerland) · 2024Review
- Article
- Imaging immunomodulatory treatment responses in a multiple sclerosis mouse model using hyperpolarizedCommunications medicine · 2023Article
- Unmet needs and gaps in the identification of secondary progression in multiple sclerosis: a Southern Italy healthcare professionals' perspective.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023Review
- Radiochemical Synthesis and Evaluation of 3-[ACS chemical neuroscience · 2022Article
- TowardBiosensors · 2022Review
- Comparison ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- Comparative Assessment of TSPO Modulators on Electroencephalogram Activity and Exploratory Behavior.Frontiers in pharmacology · 2022Article
- Clinical and neuroimaging findings in MOGAD-MRI and OCT.Clinical and experimental immunology · 2021Review
- Gray matter blood-brain barrier water exchange dynamics are reduced in progressive multiple sclerosis.Journal of neuroimaging : official journal of the American Society of Neuroimaging · 2021Article
- Neuroimaging Correlates of Cognitive Dysfunction in Adults with Multiple Sclerosis.Brain sciences · 2021Review
- Radiochemical Synthesis and Evaluation in Non-Human Primates of 3-[ACS chemical neuroscience · 2021Article
- In Vivo Proton Exchange Rate (kJournal of magnetic resonance imaging : JMRI · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBrain PET imaging with different tracers is mainly clinically used in the field of neurodegenerative diseases and brain tumors. In recent years, the potential usefulness of PET has also gained attention in the field of MS. In fact, MS is a complex disease and several processes can be selected as a target for PET imaging. The use of PET with several different tracers has been mainly evaluated in the research setting to investigate disease pathophysiology (i.e. phenotypes, monitoring of progression) or to explore its use a surrogate end-point in clinical trials.
resultsWe have reviewed PET imaging studies in MS in humans and animal models. Tracers have been grouped according to their pathophysiological targets (ie. tracers for myelin kinetic, neuroinflammation, and neurodegeneration). The emerging clinical indication for brain PET imaging in the differential diagnosis of suspected tumefactive demyelinated plaques as well as the clinical potential provided by PET images in view of the recent introduction of PET/MR technology are also addressed.
conclusionWhile several preclinical and fewer clinical studies have shown results, full-scale clinical development programs are needed to translate molecular imaging technologies into a clinical reality that could ideally fit into current precision medicine perspectives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.